■转染期间重排(RET)基因代表了仅在1%-2%的病例中发生的非小细胞肺癌(NSCLC)中罕见的驱动突变,有针对性的致癌作用。尽管免疫疗法在具有野生型驱动基因的晚期NSCLC中证明了显着疗效,其在RET融合阳性患者中的有效性尚待确定.
■本荟萃分析旨在系统评估RET融合阳性NSCLC患者免疫治疗的有效性。
■和方法:系统地搜索PubMed和WebofScience数据库以进行相关研究。结果包括客观反应率(ORR),疾病控制率(DCR),无进展生存期(PFS),提取总生存期(OS)进行进一步分析。
■这项荟萃分析纳入了涉及7145名患者的10项真实世界证据(RWE)研究。就肿瘤反应而言,合并的ORR和DCR分别为24.0%和61.0%,分别。关于生存分析,合并的中位PFS和中位OS分别为4.17个月[95%置信区间(CI):3.40-5.02)和17.22个月(95%CI:11.58-23.91)],分别。亚组分析表明,在ORR方面,免疫疗法加化疗优于单一免疫疗法,DCR,和中位数PFS,分别为43%(95%CI:31%-55%)和17%(95%CI:11%-25%),74%(95%CI:60%-84%)与45%(95%CI:31%-59%)和6.69个月(95%CI:4.91-8.93)与2.96个月(95%CI:2.25-3.78),分别。
■到目前为止,RET融合似乎与NSCLC患者对免疫治疗的反应不良有关。免疫疗法联合化疗似乎比单一免疫疗法提供更大的临床益处。
UNASSIGNED: The Rearranged during Transfection (RET) gene represents a rare driver mutation in non-small cell lung cancer (NSCLC) occurring in only 1 %-2 % of cases, with implications in targeted carcinogenesis. Despite the significant efficacy demonstrated by immunotherapy in advanced NSCLC with wild-type driver genes, its validation in RET fusion-positive patients is yet to be established.
UNASSIGNED: This meta-analysis aims to systematically evaluate the effectiveness of immunotherapy in patients with RET fusion-positive NSCLC.
UNASSIGNED: and Methods: PubMed and Web of Science databases were systematically searched for relevant studies. Outcomes including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were extracted for further analysis.
UNASSIGNED: Ten real-world evidence (RWE) studies involving 7145 patients were enrolled in this meta-analysis. In terms of tumor response, the pooled ORR and DCR were 24.0 % and 61.0 %, respectively. Regarding survival analysis, the pooled median PFS and median OS were 4.17 months [95 % confidence interval (CI): 3.40-5.02) and 17.22 months (95 % CI: 11.58-23.91)], respectively. Subgroup analyses showed that immunotherapies plus chemotherapy were superior to single-immunotherapy in terms of ORR, DCR, and median PFS, which were 43 % (95 % CI: 31%-55 %) vs. 17 % (95 % CI: 11%-25 %), 74 % (95 % CI: 60%-84 %) vs. 45 % (95 % CI: 31%-59 %) and 6.69 months (95 % CI: 4.91-8.93) vs. 2.96 months (95 % CI: 2.25-3.78), respectively.
UNASSIGNED: To date, RET fusions appear to be associated with poor response to immunotherapy in NSCLC patients, and immunotherapy combined with chemotherapy seems to offer greater clinical benefits than mono-immunotherapy.